Actionable news
All posts from Actionable news
Actionable news in AZN: ASTRAZENECA PLC,

AstraZeneca Is Now a Competitive Threat to Tesaro in Ovarian Cancer Maintenance Therapy

AstraZeneca's (AZN) Lynparza significantly delayed the recurrence of tumors in patients with ovarian cancer compared to a placebo, according to results from a phase III study announced by the company Wednesday.

Lynparza belongs to a closely followed class of cancer drugs known as PARP inhibitors. Wednesday's positive study results, if confirmed, position Lynparza for expanded U.S. approval as a maintenance therapy in ovarian cancer.

This is the same indication Tesaro (TSRO) is seeking as the first approval for its competing PARP...